Zoetis: Synovex Grows Jobs Along with Cattle
Zoetis, the animal drug developer spun out of Pfizer in February, told GEN this week that its plan to hire up to 30 more workers at its Lincoln, NE, manufacturing plant had nothing to do with current or projected future demand.
“It is solely the production of Synovex and transfer of production from a third party that sparked the expansion in Lincoln, not increased demand for any other products,” Zoetis spokesman Bill Price said.
Synovex is Zoetis’ family of growth hormone implants for beef cattle. Until now, Zoetis and predecessor Pfizer have been producing the drug through an undisclosed third-party manufacturer. The new company wants to bring production in-house—adding up to 30 jobs at peak production to the site’s current workforce of more than 500.
Synovex will join several Zoetis products manufactured in Lincoln—including Bovi-Shield Gold® and RespiSure One®, both for livestock, and Rimadyl® for dogs. Lincoln is one of Zoetis’ largest internal manufacturing operations, a roughly 1 million-square-foot facility that serves as the company’s global center for making animal health vaccines. The plant produces 1,200 finished goods for more than 100 markets annually.
Zoetis won’t disclose the expansion cost, but will say it plans to break ground later this summer on the 19,000 square-foot, three-story expansion, for which the company has begun early stages of planning and construction.
“Construction is expected to be completed in 2014, but it is too early in the process to speculate on when we can expect the peak number of new jobs to be created,” Price said.